Acute Kidney Injury in Myeloid Leukemia of Down Syndrome: Risk Factors and Outcomes
DOI:
https://doi.org/10.31584/jhsmr.2022916Keywords:
acute kidney injury, childhood acute leukemia, down syndrome, myeloid leukemia of Down syndromeAbstract
Objective: To identify the risk factors and describe the outcomes of patients who developed acute kidney injury (AKI) during treatment for myeloid leukemia of Down syndrome (ML-DS).
Material and Methods: The medical records of 23 Down syndrome patients under the age of 15 who had been diagnosed with acute myeloid leukemia (AML) and were being treated at a major tertiary care referral facility in Southern Thailand were reviewed. The identification of factors associated with AKI was done using logistic regression. The Kaplan-Meier method was used to calculate survival probabilities.
Results: Eight (34.8%) patients developed AKI during their course of chemotherapy with a median time from the first visit to the AKI event of 1.1 (IQR 0.7, 3.1) months. Higher levels of blast cells (OR: 1.19, 95% CI: 1.05-1.98) and septic shock during the course of chemotherapy (OR: 621.1, 95% CI: 2.40-Inf.) were independently associated with AKI. The 1-year overall survival rate was 26.1%. The median survival times among those who developed AKI and those who did not were 1.94 and 10.7 months, respectively
Conclusion: About one-third of the cases with ML-DS in our cohort developed AKI during the course of chemotherapy. The risk factors of AKI were higher peripheral blast count and septic shock during chemotherapy.
References
Hasle H, Clemmensen IH, Mikkelsen M. Risks of leukaemia and solid tumours in individuals with Down’s syndrome. Lancet 2000;355:165–9.
Boucher AC, Caldwell KJ, Crispino JD, Flerlage JE. Clinical and biological aspects of myeloid leukemia in Down syndrome. Leukemia 2021;35:3352–60.
Marlow EC, Ducore J, Kwan ML, Cheng SY, Bowles EJA, Greenlee RT, et al. Leukemia risk in a cohort of 3.9 million children with and without Down syndrome. J Pediatr 2021;234: 172-80.e3.
Goldsby RE, Stratton KL, Raber S, Ablin A, Strong LC, Oeffinger K, et al. Long-term sequelae in survivors of childhood leukemia with Down syndrome: A Childhood Cancer Survivor Study report. Cancer 2018;124:617–25.
Hefti E, Blanco JG. Anthracycline-related cardiotoxicity in patients with acute myeloid leukemia and Down syndrome: a literature review. Cardiovasc Toxicol 2016;16:5–13.
Palle J, Frost BM, Peterson C, Gustafsson G, Hellebostad M, Kanerva J, et al. Doxorubicin pharmacokinetics is correlated to the effect of induction therapy in children with acute myeloid leukemia. Anticancer Drugs 2006;17:385–92.
O’Brien MM, Taub JW, Chang MN, Massey GV, Stine KC, Raimondi SC, et al. Cardiomyopathy in children with Down syndrome treated for acute myeloid leukemia: a report from the Children’s Oncology Group Study POG 9421. J Clin Oncol 2008;26:414–20.
Park PG, Hong CR, Kang E, Park M, Lee H, Kang HJ, et al. Acute kidney injury in pediatric cancer patients. J Pediatr 2019;208:243–50.
Du Plessis L, Rassekh SR, Mammen C. High incidence of acute kidney injury during chemotherapy for childhood acute myeloid leukemia. Pediatr Blood Cancer 2018;65.
Limratchapong C, Sophark P, Vachvanichsanong P, McNeil EB, Chotsampancharoen T. Acute kidney injury and childhood acute myeloid leukemia. Pediatr Nephrol [serial on the Internet]. 2022 [cited 2022 Apr 24]. Available from: https://doi.org/10.1007/s00467-022-05506-4
Creutzig U, Ritter J, Schellong G. Identification of two risk groups in childhood acute myelogenous leukemia after therapy intensification in study AML-BFM-83 as compared with study AML-BFM-78. AML-BFM Study Group. Blood 1990;75:1932– 40.
Creutzig U, Zimmermann M, Lehrnbecher T, Graf N, Hermann J, Niemeyer CM, et al. Less toxicity by optimizing chemotherapy, but not by addition of granulocyte colony-stimulating factor in children and adolescents with acute myeloid leukemia: results of AML-BFM 98. J Clin Oncol 2006;24:4499–506.
Cooper TM, Franklin J, Gerbing RB, Alonzo TA, Hurwitz C, Raimondi SC, et al. AAML03P1, a pilot study of the safety of gemtuzumab ozogamicin in combination with chemotherapy for newly diagnosed childhood acute myeloid leukemia: a report from the Children’s Oncology Group. Cancer 2012;118:761–9.
Gamis AS, Alonzo TA, Perentesis JP, Meshinchi S. Children’s Oncology Group’s 2013 blueprint for research: acute myeloid leukemia. Pediatr Blood Cancer 2013;60:964–71.
Xavier AC, Ge Y, Taub J. Unique clinical and biological features of leukemia in Down syndrome children. Expert Rev Hematol 2010;3:175–86.
Kellum JA, Lameire N, Aspelin P, Barsoum RS, Burdmann EA, Goldstein SL, et al. Kidney disease: Improving global outcomes (KDIGO) acute kidney injury work group. KDIGO Clinical Practice Guideline for Acute Kidney Injury. Kidney Int Suppl 2012;2:1–138.
Schwartz GJ, Brion LP, Spitzer A. The use of plasma creatinine concentration for estimating glomerular filtration rate in infants, children, and adolescents. Pediatr Clin North Am 1987;34:571– 90.
Schwartz GJ, Work DF. Measurement and estimation of GFR in children and adolescents. Clin J Am Soc Nephrol 2009;4:1832–43.
Cairo MS, Bishop M. Tumour lysis syndrome: new therapeutic strategies and classification. Br J Haematol 2004;127:3–11.
Goldstein B, Giroir B, Randolph A. International Pediatric Sepsis Consensus Conference: definitions for sepsis and organ dysfunction in pediatrics. Pediatr Crit Care Med 2005;6:2–8.
Fisher BT, Zaoutis TE, Leckerman KH, Localio R, Aplenc R. Risk factors for renal failure in pediatric patients with acute myeloid leukemia: a retrospective cohort study. Pediatr Blood Cancer 2010;55:655–61.
Creutzig U, Büchner T, Sauerland MC, Zimmermann M, Reinhardt D, Döhner H, et al. Significance of age in acute myeloid leukemia patients younger than 30 years. Cancer 2008;112:562–71.
Rubnitz JE, Pounds S, Cao X, Jenkins L, Dahl G, Bowman WP, et al. Treatment outcome in older patients with childhood acute myeloid leukemia. Cancer 2012;118:6253–9.
Gamis AS, Woods WG, Alonzo TA, Buxton A, Lange B, Barnard DR, et al. Increased age at diagnosis has a significantly negative effect on outcome in children with Down syndrome and acute myeloid leukemia: a report from the Children’s Cancer Group Study 2891. J Clin Oncol 2003;21:3415–22.
Creutzig U, Reinhardt D, Diekamp S, Dworzak M, Stary J, Zimmermann M. AML patients with Down syndrome have a high cure rate with AML-BFM therapy with reduced dose intensity. Leukemia 2005;19:1355–60.
Craze JL, Harrison G, Wheatley K, Hann IM, Chessells JM. Improved outcome of acute myeloid leukaemia in Down’s syndrome. Arch Dis Child 1999;81:32–7.
Riley LC, Hann IM, Wheatley K, Stevens RF. Treatment-related deaths during induction and first remission of acute myeloid leukaemia in children treated on the Tenth Medical Research Council acute myeloid leukaemia trial (MRC AML10). The MCR Childhood Leukaemia Working Party. Br J Haematol 1999;106:436–44.
Dix D, Cellot S, Price V, Gillmeister B, Ethier MC, Johnston DL, et al. Association between corticosteroids and infection, sepsis, and infectious death in pediatric acute myeloid leukemia (AML): results from the Canadian Infections in AML Research Group. Clin Infect Dis 2012;55:1608–14.
Abildgaard L, Ellebæk E, Gustafsson G, Abrahamsson J, Hovi L, Jonmundsson G, et al. Optimal treatment intensity in children with Down syndrome and myeloid leukaemia: data from 56 children treated on NOPHO-AML protocols and a review of the literature. Ann Hematol 2006;85:275.
Gamis AS. Acute myeloid leukemia and Down syndrome evolution of modern therapy--state of the art review. Pediatr Blood Cancer 2005;44:13–20.
Bruwier A, Chantrain CF. Hematological disorders and leukemia in children with Down syndrome. Eur J Pediatr 2012;171:1301–7.
Schmidt MP, Colita A, Ivanov AV, Coriu D, Miron IC. Outcomes of patients with Down syndrome and acute leukemia: a retrospective observational study. Medicine 2021;100:e27459.
Bidwell SS, Peterson CC, Demanelis K, Zarins KR, Meza R, Sriplung H, et al. Childhood cancer incidence and survival in Thailand: a comprehensive population-based registry analysis, 1990-2011. Pediatr Blood Cancer 2019;66:e27428.
Wiangnon S, Veerakul G, Nuchprayoon I, Hongeng S, Krutvecho T, Sripaiboonkij N. Childhood cancer incidence and survival 2003-2005, Thailand: study from the Thai Pediatric Oncology Group. Asian Pac J Cancer Prev 2011;12:2215–20.
Downloads
Published
How to Cite
Issue
Section
License
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
